NASDAQ: TVTX
Travere Therapeutics Inc Stock Ownership - Who owns Travere Therapeutics?

Insider buying vs selling

Have Travere Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Eric M. DubeCEO2026-10-1578,400$55.02
$4.31MSell
Eric M. DubeCEO2026-10-1537,270$54.20
$2.02MSell
Eric M. DubeCEO2026-10-15128,065$52.97
$6.78MSell
Eric M. DubeCEO2026-10-15200,000$8.93
$1.79MBuy
Eric M. DubeCEO2026-10-1543,735$26.88
$1.18MBuy
Eric M. DubeCEO2026-09-176,802$64.95
$441.80kSell
Eric M. DubeCEO2026-09-17101,691$64.59
$6.57MSell
Eric M. DubeCEO2026-09-17108,493$23.34
$2.53MBuy
Peter HeermaCCO;EVP2026-09-178,282$22.40
$185.52kBuy
Peter HeermaCCO;EVP2026-09-178,282$65.07
$538.92kSell

1 of 18

TVTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TVTX insiders and whales buy or sell their stock.

TVTX Shareholders

What type of owners hold Travere Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ruth Shepley51.05%49,000,000$2.46BInsider
Broadfin Healthcare Master Fund Ltd2.77%2,658,854$133.58MInsider
Opaleye GP LLC2.19%2,097,671$105.39MInsider
Martin Shkreli1.84%1,765,168$88.68MInsider
Eric M. Dube0.45%432,886$21.75MInsider
Marc L. Panoff0.23%221,100$11.11MInsider
Steve Aselage0.17%166,419$8.36MInsider
Alvin Shih0.16%158,334$7.95MInsider
Peter Heerma0.12%117,066$5.88MInsider
Elizabeth E. Reed0.11%105,389$5.29MInsider

1 of 3

TVTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TVTX0.12%60.41%Net SellingNet Selling
ADPT0.10%53.77%Net SellingNet Selling
IONS0.11%3.35%Net SellingNet Buying
EWTX0.11%14.35%Net SellingNet Selling
DNTH0.12%59.93%Net BuyingNet Buying

Travere Therapeutics Stock Ownership FAQ

Who owns Travere Therapeutics?

Travere Therapeutics (NASDAQ: TVTX) is owned by 0.12% institutional shareholders, 60.41% Travere Therapeutics insiders, and 39.47% retail investors. Ruth Shepley is the largest individual Travere Therapeutics shareholder, owning 49.00M shares representing 51.05% of the company. Ruth Shepley's Travere Therapeutics shares are currently valued at $2.37B.

If you're new to stock investing, here's how to buy Travere Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.